The Medical Knowledge Institute in the Netherlands and was founded in 1999 by Dr. Harold E. Founder and President Emeritus of the Albert Schweitzer Institute for Humanities, Peter J. Chairman and CEO of The Futures Health Group.

They offer information and advice refined by experience. Our faculty is drawn from some of the best institutions in the world.. The Phase I trial is an open – label, multi-center trial to evaluate the maximum tolerated dose for oral PXD101 is administered once or twice daily to establish. Patients will be treated with oral PXD101 in a dose-escalation therapy and may continue to receive up to eight or more treatment cycles each illness response. Primary objectives of the study are evaluating the safety, tolerability and pharmacokinetics of oral PXD101.Alteon Inc. announced today that a preclinical study in the 27th Annual Dialysis The Conference presented to Denver, February 18 to 20, 2007 by intraperitoneal alagebrium shows a possible role for alagebrium in the treatment of kidney disease and in addition to dialysis the investigational team of were abstract with the Best Award honor at that Meeting.

Alteon Inc.. AGEs are abnormal carb-protein interactions, tissues, organs and vessels stiffen and loose feature the course of time cause Ability been contacted with diabetic complications and other age-related diseases related The gradual collapse of the peritoneal dialysis can to the use of associated glucose-containing peritoneal solutions of an accumulation of the accumulation of AGEs on the peritoneal membrane and hence change the filtering and permeability of.